Page 17 - Lantern Pharma News Today : Breaking News, Live Up

Lantern Pharma Presents Positive Data on the Effectiveness of LP-284 in Hematologic Cancers at the 63rd American Society of Hematology (ASH) Annual Meeting

Published: December 14, 2021

/PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform...

Source: prnewswire.com

Allarity Therapeutics Announces Shareholder Acceptance of

Published: December 11, 2021

Press release Hørsholm, Denmark (December 11, 2021) — Allarity Therapeutics A/S (“Allarity A/S” or the “Company”) today announced that in...

Source: globenewswire.com

Allarity Therapeutics A/S Publishes Offer Document Offering to Acquire Company Shares in Exchange for Shares in Allarity Therapeutics, Inc. with the Intent to Complete Recapitalization

Published: November 25, 2021

24.11.2021 - Press release Hørsholm, Denmark (November 24, 2021) — Allarity Therapeutics A/S ('Allarity A/S' or the 'Company') hereby announces a voluntary offer and offer document to the shareholders of Allarity A/S to acquire all shares in Allarity A/S (the ...

Source: wallstreet-online.de

U.S. SEC Issues Order Declaring Allarity Therapeutics Inc.'s Form S-4 Registration Statement Effective Ahead of Planned Transition to U.S. Nasdaq

Published: November 5, 2021

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Source: apnews.com

Lantern Pharma Announces Abstract on Effectiveness of LP-284 in Hematologic Cancers Accepted for Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting

Published: November 4, 2021